title: Gastrointestinal tolerability of lornoxicam compared to that of naproxen in healthy male volunteers.
abstract: OBJECTIVE
  Gastrointestinal effects are common adverse effects associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Lornoxicam is a new nonsteroidal anti-inflammatory drug and its gastroduodenal tolerability was compared to that of naproxen in a randomized, double-blind, crossover study.
  
  
  METHODS
  Eighteen healthy male volunteers received lornoxicam 8 mg b.d. or naproxen 500 mg b.d. administered orally over two 7-day dosing periods. Upper endoscopy was performed by two independent investigators at the beginning and end of each dosing regimen.
  
  
  RESULTS
  Lornoxicam 8 mg b.d. caused significantly less mucosal injury than naproxen 500 mg b.d. in the stomach/duodenal bulb, as well as in the mid/distal duodenum.
  
  
  CONCLUSIONS
  These findings may have favourable implications for lornoxicam in the clinical setting, if this dose provides optimal control of arthritic pain.
authors.affiliation: Department of Gastroenterology, Ullevål Hospital, Oslo, Norway.
authors.forename: L
authors.initials: L
authors.lastname: Aabakken
authors.forename: M
authors.initials: M
authors.lastname: Osnes
authors.forename: W
authors.initials: W
authors.lastname: Frenzel
mesh_terms: D000293:Adolescent; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D016099:Endoscopy, Gastrointestinal / Q000379:methods; D005753:Gastric Mucosa / Q000187:drug effects; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000009:adverse effects*; D010894:Piroxicam / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D010894:Piroxicam; D009288:Naproxen; C059451:lornoxicam